-
1.发明申请METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF TH2 MEDIATED DISEASES 审中-公开治疗TH2介导性疾病的方法和药物组合物公开(公告)号：US20150038496A1
公开(公告)日：2015-02-05
申请号：US14349188
申请日：2012-10-03
申请人： INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) , CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S.) , INSTITUT CURIE
IPC分类号： A61K31/548 , G01N33/50 , G01N33/68
CPC分类号： A61K31/548 , C12Q1/48 , G01N33/5023 , G01N33/6875 , G01N33/6893 , G01N2333/91011 , G01N2500/00 , G01N2500/02 , G01N2500/10
摘要： The present invention relates to methods and pharmaceutical composition for the treatment of T-helper type 2 (Th2)-mediated diseases. More particularly, the present invention relates to an inhibitor of the Suv39h1-HP1a silencing pathway for use in the treatment of a T-helper type 2 (Th2)-mediated disease, in particular allergic asthma.
摘要翻译： 本发明涉及用于治疗T-辅助2型（Th2）介导的疾病的方法和药物组合物。 更具体地说，本发明涉及用于治疗T型辅助2型（Th2）介导的疾病，特别是过敏性哮喘的Suv39h1-HP1a沉默途径的抑制剂。
-
公开(公告)号：US10752668B2
公开(公告)日：2020-08-25
申请号：US15327517
申请日：2015-07-24
申请人： THERAVECTYS , INSTITUT CURIE , CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE , UNIVERSITE PIERRE ET MARIE CURIE , INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
发明人： Sophie Agaugue , Lorenzo Tibaldi , Klervi Even-Desrumaux , Dmitry Trubetskoy , Franck Perez , Sebastian Amigorena , Cécile Bauche
IPC分类号： C07K16/30 , G01N33/574 , C07K16/28 , C07K14/705 , C12N5/0783 , A61K35/17 , C07K16/00 , A61K38/00
摘要： The invention relates to the regulated expression of a chimeric antigen receptor (CAR) within a lentiviral vector. The CAR comprises a hook-binding domain that interacts with a hook, preferably encoded by the same lentiviral vector, which prevents proper processing and release of the CAR to the cell membrane. The invention encompasses vectors, methods of making the vectors, and methods of using them, including medicinal uses. The vectors can be used for administration to humans to induce immune responses and to treat cancers and tumors.
-
公开(公告)号：US11622978B2
公开(公告)日：2023-04-11
申请号：US16747198
申请日：2020-01-20
申请人： INSTITUT CURIE , Institut National de la Sante et da la Recherche Medicale (INSERM) , Centre National de la Recherche Scientifique (CNRS)
发明人： Sebastian Amigorena , Eliane Piaggio , Christel Goudot , Luigia Pace , Genevieve Almouzni , Leticia Niborski
IPC分类号： A61K35/17 , A61P35/02 , C07K14/725 , C07K14/705 , A61K45/06
摘要： The present invention relates to an engineered immune cell defective for Suv39h1. Preferably, said engineered immune cell further comprises a genetically engineered antigen receptor that specifically binds a target antigen. The present invention also relates to a method for obtaining a genetically engineered immune cell comprising a step consisting in inhibiting the expression and/or activity of Suv39h1 in the immune cell; and further optionally comprising a step consisting in introducing in the said immune cell a genetically engineered antigen receptor that specifically binds to a target antigen. The invention also encompasses said engineered immune cell for their use in adoptive therapy, notably for the treatment of cancer.
-
公开(公告)号：US11285176B2
公开(公告)日：2022-03-29
申请号：US17507748
申请日：2021-10-21
发明人： Sebastian Amigorena , Eliane Piaggio , Christel Goudot , Luigia Pace , Genevieve Almouzni , Leticia Niborski
IPC分类号： A61K35/17 , A61P35/02 , C07K14/725 , C07K14/705 , A61K45/06
摘要： The present invention relates to an engineered immune cell defective for Suv39h1. Preferably, said engineered immune cell further comprises a genetically engineered antigen receptor that specifically binds a target antigen. The present invention also relates to a method for obtaining a genetically engineered immune cell comprising a step consisting in inhibiting the expression and/or activity of Suv39h1 in the immune cell; and further optionally comprising a step consisting in introducing in the said immune cell a genetically engineered antigen receptor that specifically binds to a target antigen. The invention also encompasses said engineered immune cell for their use in adoptive therapy, notably for the treatment of cancer.
-
公开(公告)号：US20230303974A1
公开(公告)日：2023-09-28
申请号：US18018635
申请日：2021-07-30
IPC分类号： C12N5/0783 , C07K14/725 , A61K35/17 , A61P35/00
CPC分类号： C12N5/0636 , C07K14/7051 , A61K35/17 , A61P35/00
摘要： The present invention relates to an engineered immune cell defective for SOCS1. Preferably, said engineered immune cell further comprises a genetically engineered antigen receptor that specifically binds a target antigen. The present invention also relates to a method for obtaining a genetically engineered immune cell comprising a step consisting in inhibiting the expression and/or activity of SOCS1 in the immune cell; and further optionally comprising a step consisting in introducing in the said immune cell a genetically engineered antigen receptor that specifically binds to a target antigen. The invention also encompasses said engineered immune cell for their use in adoptive therapy, notably for the treatment of cancer.
-
公开(公告)号：US10968281B2
公开(公告)日：2021-04-06
申请号：US16341529
申请日：2017-10-13
申请人： INSTITUT CURIE , CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE , INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE
IPC分类号： A61K39/395 , A61K39/00 , G01N33/53 , C07K16/46 , C07K16/00 , C07K16/30 , G01N33/50 , A61K38/00
摘要： The present invention provides a new anti-LSP1 (Leukocyte specific protein 1) antibody. This new antibody allows the specific staining of inflammatory dendritic cells and can be used in diagnosis methods or as a medicament when conjugated to a drug.
-
公开(公告)号：US20210060158A1
公开(公告)日：2021-03-04
申请号：US16644159
申请日：2018-09-19
发明人： Sebastian Amigorena , Elodie Segura
IPC分类号： A61K39/395 , A61K31/404 , A61K31/407 , A61K31/352 , A61K31/353 , A61K31/7048 , A61K31/4439 , A61K31/47 , A61K31/42 , A61K31/505 , A61K31/4184 , A61K31/198 , A61K38/17 , A61K38/44 , A61P35/00
摘要： The present invention relates to an AhR agonist for use in combination with at least one immune checkpoint modulator in the treatment of cancer. The present invention also encompasses product containing an AhR agonist and at least one immune checkpoint modulator as defined in any one of the preceding, claims, as a combined preparation for simultaneous, separate or sequential use in the treatment of cancer.
-
公开(公告)号：US20200331975A1
公开(公告)日：2020-10-22
申请号：US16757409
申请日：2018-10-22
申请人： INSTITUT CURIE , INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) , CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS)
IPC分类号： C07K14/435 , C07K16/12 , C07K16/28 , C07K14/705 , C12N7/00 , C12N15/86
摘要： The present invention relates to a chimeric antigen receptor comprising: a binding domain, the full DAP 10 protein, the full DAP 12 protein, or a functional variant thereof, anda hook binding domain.The present invention also relates to a vector system comprising one or more vector comprising: a nucleic acid comprising a nucleic acid sequence encoding a chimeric antigen receptor and optionally a nucleic acid encoding a hook fusion protein, preferably comprising a streptavidin core; wherein said nucleic acids are located on the same or on different vectors; The invention also encompasses lentiviral vector particles system, host cell and kit comprising said nucleic acids or vector system. The invention also relates to lentiviral vector particles system, host cell and kit as herein disclosed for their use as a medicament, notably for immunotherapy.
-
公开(公告)号：US20240101616A1
公开(公告)日：2024-03-28
申请号：US18515805
申请日：2023-11-21
申请人： INSTITUT CURIE , INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) , CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS)
IPC分类号： C07K14/435 , C07K14/705 , C07K16/12 , C07K16/28 , C12N7/00 , C12N15/86
CPC分类号： C07K14/435 , C07K14/70517 , C07K14/70575 , C07K16/1292 , C07K16/2896 , C12N7/00 , C12N15/86 , C07K2317/622 , C07K2319/03 , C07K2319/40 , C12N2740/15042
摘要： A chimeric antigen receptor including: a binding domain, the full DAP 10 protein, the full DAP 12 protein, or a functional variant thereof, and a hook binding domain. Also, a vector system comprising one or more vector including: a nucleic acid comprising a nucleic acid sequence encoding a chimeric antigen receptor and optionally a nucleic acid encoding a hook fusion protein, preferably having a streptavidin core; wherein the nucleic acids are located on the same or on different vectors. Further, a lentiviral vector particles system, host cell and kit including the nucleic acids or vector system, and their use as a medicament, notably for immunotherapy.
-
公开(公告)号：US10576103B2
公开(公告)日：2020-03-03
申请号：US16425008
申请日：2019-05-29
申请人： INSTITUT CURIE , Institut National de la Sante et da la Recherche Medicale (INSERM) , Centre National de la Recherche Scientifique (CNRS)
IPC分类号： A61K35/17 , A61P35/02 , C07K14/725 , C07K14/705 , A61K45/06
摘要： The present invention relates to an engineered immune cell defective for Suv39h1. Preferably, said engineered immune cell further comprises a genetically engineered antigen receptor that specifically binds a target antigen. The present invention also relates to a method for obtaining a genetically engineered immune cell comprising a step consisting in inhibiting the expression and/or activity of Suv39h1 in the immune cell; and further optionally comprising a step consisting in introducing in the said immune cell a genetically engineered antigen receptor that specifically binds to a target antigen. The invention also encompasses said engineered immune cell for their use in adoptive therapy, notably for the treatment of cancer.
-
-
-
-
-
-
-
-
-
搜索结果
10 条记录 (耗时 0.031 秒)
